Prostaglandin-endoperoxide synthase 2, Mitogen-activated protein kinase 14, Matrix metallopeptidase 9, Mitogen-activated protein kinase 1, NF-kappa-B inhibitor alpha, Caspase-8 (PTGS2, MAPK14, MMP9, MAPK1, NFKBIA, CASP8)

The target set comprising PTGS2, MAPK14, MMP9, MAPK1, NFKBIA, and CASP8 represents a cluster of proteins central to the regulation of inflammation, cell survival, and apoptosis. Prostaglandin-endoperoxide synthase 2 (PTGS2), also known as COX-2, is an enzyme responsible for synthesizing pro-inflammatory prostaglandins (UniProt P35354). Mitogen-activated protein kinases MAPK14 (p38 alpha) and MAPK1 (ERK2) serve as critical signaling hubs that translate extracellular stimuli into cellular responses like cytokine production and growth (UniProt Q16539, P28482). Matrix metallopeptidase 9 (MMP9) is a zinc-dependent protease that degrades extracellular matrix components, playing a vital role in tissue remodeling and cancer metastasis (UniProt P14780). NFKBIA (IkappaB-alpha) acts as a key regulator of the NF-kappa-B transcription factor by sequestering it in the cytoplasm, thereby controlling the expression of numerous immune-response genes (UniProt P25963). Caspase-8 (CASP8) is a cysteine protease that initiates the extrinsic pathway of apoptosis, ensuring the removal of damaged or infected cells (UniProt Q14790). Together, these molecules are frequently analyzed in network pharmacology to understand the multi-target effects of anti-inflammatory and anti-cancer therapeutics, though their broad biological roles necessitate careful therapeutic window management to avoid systemic toxicity.

Other names

Cyclooxygenase-2 (COX-2)p38 mitogen-activated protein kinase alpha92 kDa type IV collagenaseExtracellular signal-regulated kinase 2 (ERK2)I-kappa-B-alphaApoptotic cysteine protease

This group of targets is modulated through diverse mechanisms: PTGS2 is inhibited to reduce prostaglandin synthesis; MAPK14 and MAPK1 are inhibited to block stress and growth signaling pathways; MMP9 is inhibited to prevent extracellular matrix degradation; NFKBIA is stabilized by proteasome inhibitors to prevent NF-kappa-B nuclear translocation; and CASP8 is targeted to initiate or modulate the extrinsic apoptotic pathway.